Cellular respiration

BERG To Present Latest Glioblastoma [GBM] Treatment Data At Society For Neuro-Onocology 2021 Meeting

Retrieved on: 
Wednesday, July 14, 2021
Cellular respiration, Branches of biology, Mitochondria, Biology, Natural sciences, Biochemistry, Carbohydrates, Glycolysis, Mitochondrion

"Brain cancers, such as GBM, are destroying patients and their families," said Dr.Niven R. Narain, CEO, President and Co-founder of BERG.

Key Points: 
  • "Brain cancers, such as GBM, are destroying patients and their families," said Dr.Niven R. Narain, CEO, President and Co-founder of BERG.
  • BPM 31510 is a unique therapeutic modality, that specifically targets cell metabolism and shifts the cancer's glycolytic dependency toward mitochondrial oxidative phosphorylation.
  • BERG LLC is a clinical-stage, artificial intelligence-powered biotech leveraging its proprietary platform, Interrogative Biology, to map disease and revolutionize treatments across oncology, neurology and rare diseases.
  • We are grateful to our patient and family partners for their participation in these critical efforts to improve cancer care.

Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction

Retrieved on: 
Friday, July 9, 2021
Branches of biology, Biology, Cellular respiration, Mitochondrial genetics, Cell biology, Fatty acids, Mitochondria, Mitochondrion, Mitochondrial disease, Beta oxidation, Acyl-CoA, ATP-sensitive potassium channel

The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.

Key Points: 
  • The waiver for Ms. Johnson will take effect on July 13, 2021 and the shares may be sold on or after such date.
  • Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
  • Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Reneo Pharmaceuticals to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Mitochondrial genetics, Mitochondrial diseases, Cellular respiration, Mitochondria, Mitochondrion, Mitochondrial disease, Aerie Pharmaceuticals, Neuropathy, ataxia, and retinitis pigmentosa

SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be held virtually on July 13-14, 2021.

Key Points: 
  • SAN DIEGO, July 07, 2021 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that it will provide a corporate update and participate in one-on-one investor meetings at the Ladenburg Thalmann 2021 Healthcare Conference, to be held virtually on July 13-14, 2021.
  • Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
  • Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.

Worldwide Malic Acid Industry to 2029 - by Application Type and Geography - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 15, 2021
Retail, Science, Other Science, Food, Beverage, Chemical substances, Chemical compounds, Chemistry, Dicarboxylic acids, Food acidity regulators, Cellular respiration, Malic acid, Acids in wine, Malic, Bodybuilding supplement

This report offers strategic insights into the global malic acid industry along with the market size and estimates for the duration 2019 to 2029.

Key Points: 
  • This report offers strategic insights into the global malic acid industry along with the market size and estimates for the duration 2019 to 2029.
  • Malic acid, it is adicarboxylic acid which is used an active ingredient in many food products.
  • Furthermore, rising demand of the fruit flavored drinks and protein drinks is substantially growing the malic acid market.
  • Furthermore, approval of malic acid from different regulatory agency for food processing is projected to augment the overall market growth over the coming years.

Reneo Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Cellular respiration, Mitochondrion, Mitochondrial disease, Beta oxidation, Adenosine triphosphate, Acyl-CoA, Mitochondrial DNA

b'Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).

Key Points: 
  • b'Reneo is a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP).
  • Reneo is developing REN001 to modulate genes critical to metabolism and generation of ATP, which is the primary source of energy for cellular processes.
  • REN001 has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation, and may increase production of new mitochondria.\n'

Stealth BioTherapeutics to Report First Quarter Financial Results on Tuesday, May 18, 2021

Retrieved on: 
Tuesday, May 11, 2021
Branches of biology, Molecular biology, Cellular respiration, Mitochondria, Mitochondrion, Mitochondrial disease, Mito, Biology

b"BOSTON, May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report first quarter 2021 financial results on Tuesday, May 18, 2021, before the market opens.\nManagement will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.

Key Points: 
  • b"BOSTON, May 11, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announcedthat it will report first quarter 2021 financial results on Tuesday, May 18, 2021, before the market opens.\nManagement will host a conference call at8:30 am ETthat day to discuss the financial results and provide a general business update.
  • The call can be accessed by dialing (877)-407-0989 (domestic) or (201)-389-0921 (international) and referencing conference ID 13719019.
  • A live audio webcast of the event can be accessed by visiting the Investors & News section of Stealth's Investor website, https://investor.stealthbt.com/ .
  • Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function.

CohBar to Announce 2021 First Quarter Financial Results and Provide Business Update on May 17, 2021

Retrieved on: 
Monday, May 3, 2021
Branches of biology, Cellular respiration, Mitochondria, Mitochondrion, Peptide, XC2, Mitochondrial disease, Biology

To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13718702.

Key Points: 
  • To access the recording please dial (844) 512-2921 in the U.S. and Canada, or (412) 317-6671 internationally, and reference Conference ID# 13718702.
  • To date, the company has discovered more than 100 mitochondrial derived peptides and generated over 1,000 analogs.
  • CohBar\xe2\x80\x99s efforts focus on the development of these peptides into therapeutics that offer the potential to address a broad range of diseases\xc2\xa0associated with the underlying impact of mitochondrial dysfunction.
  • The company\xe2\x80\x99s lead compound, CB4211, is in the Phase 1b stage of a Phase 1a/1b clinical trial for NASH and obesity.

Newest Breakthrough in Anti-aging Discovered

Retrieved on: 
Wednesday, April 28, 2021
Branches of biology, Nucleotides, Academic disciplines, Cellular respiration, Coenzymes, Photosynthesis, Ageing, Articles, Nicotinamide adenine dinucleotide, Life extension, NMN

As we age, the level of NAD+ decreases, and this decrease, which intensifies after the age of 30, is a principal trigger in the process of aging.

Key Points: 
  • As we age, the level of NAD+ decreases, and this decrease, which intensifies after the age of 30, is a principal trigger in the process of aging.
  • Thus, boosting NAD+ levels is the key to the fountain of youth: anti-aging.\nHowever, NAD+ is an unstable compound which renders it impractical as a direct supplement or injection.
  • FOUNT\'Y NMN 12000\'s effectiveness also does not diminish gradually in time, as is the case with other NMN supplement brands, due to its special proprietary formula of activators and blockers.
  • It has also received a Certificate of GMP issued by Consumer Health Products Canada.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/newest-breakthrough-in-anti-agin...\n'

Global Malic Acid Market Report 2021: Industry Trends, Share, Size, Growth, Opportunity and Forecasts, 2015-2020 & 2021-2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021
Food, Beverage, Retail, Dicarboxylic acids, Chemical compounds, Chemistry, Physical sciences, Food acidity regulators, Cellular respiration, Malic acid, Malic, Acids in wine, C4H6O5

b'The "Malic Acid Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global malic acid market reached a volume of 88.5 Kilotons in 2020.

Key Points: 
  • b'The "Malic Acid Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global malic acid market reached a volume of 88.5 Kilotons in 2020.
  • Looking forward, the global malic acid market to exhibit moderate growth during the next five years.\nMalic acid is a dicarboxylic acid made by all living organisms and has the molecular formula C4H6O5.
  • Apart from this, malic acid finds applications in the detergent, health, and cosmetics and personal care industries.\nGlobal Malic Acid Market Drivers:\nIn recent years, the growing use of malic acid for manufacturing sugarless confectioneries has escalated its demand among obese and diabetic people.
  • In the pharmaceutical industry, malic acid is used in the production of medical products including cough syrups, throat lozenges, toothpaste, mouthwash and health supplements such as protein shakes and nutrition bars.\nThe competitive landscape of the market has also been examined with some of the key players being Changmao Biochem, Bartek, Thirumalai Chemicals, Fuso Chemical Co., Ltd, Polynt, Yongsan Chemicals, Anhui Sealong Biotechnology, The Chemical Company, Miles Chemical, Isegen South Africa, Spectrum Chemical, Mitsubishi Chemical, Corbion, Mubychem Group and Tate & Lyle.\nKey Questions Answered in This Report:\nHow has the global malic acid market performed so far and how will it perform in the coming years?\nWhat are the key regional markets in the global malic acid industry?\nWhat has been the impact of COVID-19 on the global malic acid industry?\nWhat is the breakup of the global malic acid market on the basis of product type?\nWhat is the breakup of the global malic acid market on the basis of application?\nWhat are the various stages in the value chain of the global malic acid market?\nWhat are the key driving factors and challenges in the global malic acid market?\nWhat is the structure of the global malic acid market and who are the key players?\nWhat is the degree of competition in the global malic acid market?\nHow is malic acid manufactured?\n'

LUCA Science Announces the Opening of a New Subsidiary in the UK and Expansion on the Collaboration With the University of Oxford on the Development of Novel Mitochondrial Therapeutics

Retrieved on: 
Wednesday, April 7, 2021
Research, Baby, Maternity, Genetics, Biotechnology, University, Pharmaceutical, Consumer, Health, Science, Education, Branches of biology, Biology, Cell biology, Mitochondria, Human pregnancy, Cellular respiration, Mitochondrion, Intrauterine growth restriction, Bioenergetics

LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Sciences proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies.

Key Points: 
  • LUCA Science UK will focus on research collaborations with the University of Oxford using LUCA Sciences proprietary Mitochondria therapy in advancing treatment of intra-uterine growth restriction (IUGR) for mothers and babies.
  • LUCA Science UK will be based in Oxford.
  • LUCA Science is a pioneer in developing a new class of mitochondrial therapy to restore cellular bioenergetics in dysfunctional tissues.
  • LUCA Science has developed a novel method to isolate proprietary functional mitochondria which can then be stored and delivered as a biopharmaceutical agent.